

Chesi Alessandra (Orcid ID: 0000-0002-0954-7446)  
Hankenson Kurt (Orcid ID: 0000-0003-1432-747X)  
Grant Struan (Orcid ID: 0000-0003-2025-5302)

## **CRISPR-Cas9 mediated genome editing confirms *EPDR1* as an e GWAS-implicated '*STARD3NL*' locus**

James A. Pippin B.A.<sup>1</sup>, Alessandra Chesi Ph.D.<sup>1</sup>, Yadav Wagley Ph.D.  
Matthew C. Pahl Ph.D.<sup>1</sup>, Kenyaita M. Hodge B.A.<sup>6</sup>, Matthew E. Johnson  
Ph.D.<sup>1,3</sup>, Kurt D. Hankenson, D.V.M., Ph.D.<sup>2</sup> and Struan F.A. Grant Ph.D.<sup>4</sup>

<sup>1</sup>Center for Spatial and Functional Genomics, Children's Hospital of Philadelphia, Philadelphia, United States, <sup>2</sup>Department of Orthopedic Surgery, University of Michigan, Ann Arbor, United States, <sup>3</sup>Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, United States, <sup>4</sup>Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, United States, <sup>5</sup>Divisions of Genetics and Endocrinology, Children's Hospital of Philadelphia, Philadelphia, United States, <sup>6</sup>Genetics and Molecular Biology Graduate School, Emory University, Atlanta, United States

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this manuscript and the final published version. This article is protected by copyright. All rights reserved. Please cite this article as doi: 10.1002/ibm4.10521

**ABSTRACT**

Genome wide association studies (GWAS) have discovered genetic signals associated with bone mineral density (BMD), but typically not the precise localization of the causal variants. Here, we used an intersecting genome-wide promoter-focused Capture C and ATAC-seq approach to identify enhancer-promoter contacts in human mesenchymal progenitor cell (hMSC)-derived osteoblasts, where we identified consistent contacts between the *EPDR1* promoter and multiple BMD-associated causal variants at the '*STARD3NL*' locus. We further showed that RNAi-mediated knockdown of *STARD3NL* expression in hMSC-derived osteoblasts led to inhibition of osteoblast differentiation. To characterize the physical connection between these putative non-coding regulatory elements at the *STARD3NL* locus and the *EPDR1* gene, we conducted CRISPR-Cas9 genome editing across the single open chromatin region harboring candidates for the causal variants, including rs1524068, rs6975644 and rs940347, all in close proximity to each other. Western immunoblotting revealed dramatic and consistent downregulation of *EPDR1* in CRISPR-edited differentiated osteoblast cells. Consistent with *EPDR1* expression, alkaline phosphatase staining was also markedly reduced in the edited differentiated cells. CRISPR-Cas9 genome editing in the hFOB1.19 cell model supports a model where this regulatory region harboring GWAS-implicated variation operates as an enhancer for the *EPDR1* gene.

## INTRODUCTION

Bone mineral density (BMD) is a key clinical measure used to assess the risk of the age-related disease, osteoporosis<sup>(1)</sup>. Low BMD is associated with fractures, including low trauma events in osteoporosis patients<sup>(2)</sup>. BMD is highly heritable. Genome-wide association studies (GWAS) having already identified hundreds of loci associated with disease risk across both adults<sup>(3)</sup> (1) and children<sup>(4)</sup> (5). While some progress has been made in recent years with development of new methods to treat osteoporosis<sup>(6)</sup>, the genetic investigation of BMD loci identified by GWAS should reveal target genes and potentially novel therapeutic avenues for prevention and treatment of osteoporosis.

Often the sentinel single nucleotide polymorphism (SNP) identified in GWAS is not the causal SNP but instead a proxy SNP in close linkage disequilibrium with the causal SNP<sup>(8)</sup>. We recently published a high-resolution variant-to-gene map of BMD GWAS loci in a disease-relevant cellular context: human mesenchymal stem cell-derived osteoblasts (hMSCs)<sup>(9)</sup>. We placed two constraints on our data derived from cells differentiated into osteoblasts, first that SNPs in strong linkage disequilibrium with the GWAS sentinel variant must be accessible as determined by Assay for Transposase-Accessible Chromatin using sequencing (ATAC-seq), and second that these accessible SNPs must be in direct physical contact with an accessible promoter as determined by

In that initial study, *EPDR1* (encoding ependymin related protein 1) was one of the 10 most highly implicated genes we examined and demonstrated an influence on both osteoblast and adipogenesis. The *EPDR1* gene resides at the 'STARD3NL' locus (see Figure 1) with a minor allele frequency: ~35%), and down-regulation of its expression (RNAi) in BMP2-induced hMSC-derived osteoblasts revealed a decrease in alkaline phosphatase (ALP) and Alizarin red S (ARS) staining, two fundamental markers of osteoblastogenesis<sup>(9)</sup>. Further analysis revealed a reciprocal role for *EPDR1* in the differentiation of the same hMSCs. Silencing of *EPDR1* increased the adipogenic differentiation during adipogenic differentiation of hMSCs, which was accompanied by up-regulation of *C/EBP* alpha and *PPAR* gamma, two key adipogenic transcription factors.

While our RNAi approach provided valuable insight into the potential role of *EPDR1* in osteoblast differentiation, it did not prove a direct regulatory connection between the implicated proxy SNPs and this putative effector gene. To determine if the associated tight proxy SNP cluster resides in a cis-regulatory element of the *EPDR1* gene, we sought to delete the open chromatin region (OCR) harboring the proxy SNPs to the sentinel (which are in strong linkage disequilibrium (LD) and are associated using clustered regularly interspaced short palindromic repeat Cas9 editing (CRISPR-Cas9) mediated gene editing (**Figure 1**). We have successfully applied

approach in primary hMSCs, given their lack of proliferation ability. Here, as an alternative cell model, an immortalized human fetal osteoblastic cell line was used for the characterization of regulatory regions for human osteoblastogenesis. This cell line, which is easily passaged and expanded, a key requirement for CRISPR targeting, contains a temperature-sensitive mutant, tsA58, of the SV40 large T antigen that allows edited cells to proliferate under permissive conditions (33.5°C), and to differentiate into osteoblasts at a higher temperature (39.5°C) <sup>(11)</sup>. This allowed us to study the variant-to-gene contact between the proxy SNPs and the *EPDR1* gene at the *'STARD3NL'* locus at various stages of differentiation.

## MATERIALS AND METHODS

### Cell Culture

hFOB1.19 and 293T cells were cultured in the recommended media under standard culture conditions at 33.5°C and 37°C respectively. Differentiation into mature osteoblasts was accomplished by growing the cells at 39°C in the presence of dexamethasone and ascorbic acid in the presence of 10% fetal bovine serum (FBS) in the first 48 hours of the experiments. (see supplemental **Detailed Materials and Methods** for details).

### RNAi treatment

Cells were seeded in 12-well plates and RNAi transfections were performed using a mixture of four ON-TARGETplus siRNAs (see **Supplemental, Table 1**) according to the manufacturer's instructions. Twenty-four hours later, media was replaced with fresh growth medium. Cells designated for differentiation into mature osteoblasts were moved to 39°C and cells were allowed to grow until assayed for ALP staining after 5 weeks (see **Detailed Materials and Methods** for details).

### CRISPR Constructs, Lentivirus Production, hFOB1.19 Infection

The synthesized sgRNAs were cloned into the LentiCRISPRv2-multiple cloning site (MCS) using a modified Golden Gate assembly method<sup>(12) (13) (14)</sup> (see **Supplemental**

Freshly thawed hFOB1.19 cells were plated and allowed to adhere. Media was replaced with fresh growth media, filtered lentivirus, and Polybrene for infection. Media was replaced after 72 hrs. and cells were checked for infection (see **Supplemental Figure 1**). Lentiviral transduction efficiency was determined from both bright field live and mCherry positive cells. Cells were split post-infection into stocks and experimental plates to allow for assaying the cells at an early passage to the original cells as possible. (see supplemental **Detailed Material** for details).

### **Multiplex Sequencing**

Genomic DNA from CRISPR-edited plates was extracted, quantitated, and a 100bp proxy SNP target region was amplified by PCR (see **Supplemental Figure 1** and **Supplemental Table 1**) in three concurrent reactions. The final PCR products were sequenced with sequencing primers approximately 50bp upstream of each CRISPR cut site to get coverage for all possible CRISPR-cas9 splicing sites. To eliminate primer dimers, the PCR reactions were followed by a purification step. Libraries were checked on a Bioanalyzer 2100 (Agilent) for quality before being pooled. Libraries were sequenced on the MiSeq System (Illumina).

## Alkaline Phosphatase Assay

ALP staining was assessed as described in previous studies with CRISPR-edited hFOB1.19 cells were seeded in two 12-well plates all The following day, one plate was moved to 39.5°C and allowed to diff the other remained at 33.5°C. On the day of the ALP assay, fresh fixa were prepared, media was removed, and cells were washed with DPB plate, washed with ultrapure water, and staining solution was applied development of color. Once staining was complete, cells were wash allowed to air dry. Plates were photographed and images were conver quantification using Image J software as previously described<sup>(9)</sup>. (see **Materials and Methods** for details).

## Reverse Transcription-quantitative Polymerase Chain Reaction (

RNA was isolated from CRISPR-edited hFOB1.19 cells after 7 da (39.5°C). RNA was subsequently purified, converted into cDNA, and s gene specific primers (see **Supplemental Table 1**). Results were exp GAPDH and fold change calculated using C<sub>q</sub> ( $\Delta R$ ) values and the cor



with EPDR1 antibody (Abcam, ab197932) and  $\alpha$ -Tubulin antibody (Santa Cruz Biotechnology, sc-58666). On the following day, membranes were washed, incubated with Horseradish Peroxidase (HRP) linked secondary antibodies (Santa Cruz Biotechnology), and developed with chemiluminescent substrate and visualized using the iBright System (Thermo). Quantification of Western immunoblotting bands was performed using the built-in software on the iBright system. (see supplemental **Detailed Methods** for details).

## RESULTS

### RNAi knock-down of *EPDR1* gene expression and alkaline phosphatase activity in differentiated hFOB1.19 Cells

To validate differentiated hFOB1.19 cells as a comparable model to hMSC-derived osteoblasts for our line of investigation, we examined the effect of *EPDR1* expression in hFOB1.19 cells. Our previous RNAi targeting of *EPDR1* in hMSC-derived osteoblasts resulted in lower levels of both alkaline phosphatase activity and Alizarin red S staining (ARS)<sup>(9)</sup>. ALP activity is necessary for hydroxyapatite mineralization<sup>(16)</sup>, while ARS stains for the deposition of calcium<sup>(17)</sup>. However, as hFOB1.19 cells undergo osteoblast differentiation, they do not produce an appreciable amount of mineral for detection by ARS<sup>(18)</sup>. Therefore, we elected to use ALP staining as a marker for osteoblast differentiation. To confirm the same response as observed in hMSC-derived osteoblasts, we carried out RNAi targeting of *EPDR1* expression in differentiated hFOB1.19 cells. ALP activity was markedly increased during differentiation of hFOB1.19 cells, while ARS activity was reduced in undifferentiated cells and in *EPDR1* RNAi treated cells under differentiation. This reduction was more pronounced than our observations in hMSC-derived osteoblasts (Supplemental Figure 3A and 3B). This confirmed that the hFOB1.19 cells are a suitable cellular model to study preliminary osteoblast differentiation, and that

the '*STARD3NL*' locus, which are all in close proximity (rs1524068, rs1524069, rs1524070). Given that the three proxy SNPs are harbored within a 204bp region and are highly correlated with each other with respect to LD, we designed a pooled set of three sgRNAs flanking the region on each side of the proxy SNP set to delete the entire region of open chromatin (see **Supplemental Figure 2**). mCherry expression in CRISPR targeted cells was measured after lentiviral transduction efficiency and averaged ~87% (see **Supplemental Figure 2**). This high efficiency allowed us to proceed without cell sorting; however, it is a potential drawback. As a result of this approach, all subsequent results included at least 10% mCherry positive cells.

### **PCR and multiplexed sequencing validation of pooled CRISPR hFOB1.19 cells**

PCR primers flanking the targeted region were used to amplify genomic DNA from the CRISPR edited hFOB1.19 cells (see **Supplemental Figure 2** and **Supplemental Table 1**). PCR products were further selected for specificity with a nested set of PCR primers. PCR products from both wild type and CRISPR deletions fell within the predicted size range (see **Figure 5**). The wild type product was 2,370 base pairs (bp) in size, while CRISPR-edited pooled cells ranged from 595bp to 1,739bp (PCR bands are shown in **Figure 5**). To further verify each CRISPR deletion, all PCR products were sequenced using a next generation sequencing adapter primer strategy modified from previous work (see **Supplemental Figure 2** and **Supplemental Table 1**).

### qPCR analysis of *EPDR1* RNA expression in pooled CRISPR hFOB1.19 cells

Given that distal cis-regulatory elements generally regulate gene expression in order to physically cooperate with the promoter and/or proximal upstream elements, we hypothesized that contacts between the putative causal SNP region and the promoter regulate *EPDR1* gene expression. To test this, we measured *EPDR1* mRNA levels using gene specific primers (see **Supplemental Table 1**) on control (LentiCRISPRv2-mCherry construct containing no sgRNA sequence) and differentiated hFOB1.19 cells growing for five days under either permissive or differentiated conditions. All samples were first normalized to *GAPDH* expression and then normalized to empty vector control samples, a large increase in *EPDR1* mRNA was observed in differentiated control samples, but *EPDR1* mRNA levels remained significantly lower in differentiated pooled CRISPR-edited samples (**Figure 3**). No difference in *EPDR1* expression was observed in the cells growing under undifferentiated conditions. Normalization of CRISPR samples to *GAPDH* for the corresponding permissive and differentiated controls, respectively, revealed levels of *EPDR1* mRNA in differentiated hFOB1.19 cells were reduced 3- to 7-fold compared to controls and undifferentiated cells (**Supplemental Figure 6**). Taken together, this

immunoblot analysis. As shown in **Figure 4A**, EPDR1 protein expression was significantly reduced in the pooled CRISPR-edited hFOB1.19 cells grown under differentiation conditions, but not in those grown under permissive conditions, which is consistent with the results observed for *EPDR1* mRNA levels. Quantification of both the upper band (M) and lower band (M) present across all samples showed ~70-90% decrease in EPDR1 protein levels normalized to Tubulin, but in the differentiated samples only. (**Figure 4A**)

#### **Alkaline phosphatase activity in pooled CRISPR-edited hFOB1.19 cells**

Alkaline phosphatase activity is an important biomarker of osteoblast differentiation, therefore we sought to confirm that this decrease in *EPDR1* expression was associated with differences in ALP activity in differentiated hFOB1.19 cells lacking the causal SNP region. Pooled CRISPR-edited hFOB1.19 replicates were grown under permissive and differentiation conditions for five days. Plates were stained for ALP activity in the same manner used for RNAi treated cells. As shown in **Figure 4B**, induced ALP staining was reduced in CRISPR-edited hFOB1.19 cells. Quantification of ALP staining revealed a 40-76% decrease in this staining in CRISPR-edited cells. We presume a portion of the staining in the CRISPR-edited cells is due to non-differentiated cells (approximately 10%) in our pooled replicates. This decrease in ALP activity

## DISCUSSION

In our previous study, we implicated a putative regulatory region between three BMD GWAS proxy SNPs interacting with *EPDR1*, a gene not previously involved in bone metabolism<sup>(9)</sup>. It should be noted that the previous studies of genes implicated in osteoblastogenesis using this method and the same approach more generally applied to other GWAS studies and cell model systems have sought to fully validate the regulatory connection between the SNP haplotype at the 'STARD3NL' locus and the implicated *EPDR1* gene. Deleting this region of the putative underlying causal SNP in hFOB1.19 cells by CRISPR-Cas9 perturbation for an *EPDR1* regulatory function of this region at both the RNA and protein levels, interestingly, this regulation is cell differentiation state specific. The new **Figure 1)** was not detectable by qPCR and showed no significant change in hFOB1.19 cells (data not shown). Thus, these studies also support our hypothesis that *EPDR1* plays a role in osteoblastogenesis by validating the putative regulatory effect on ALP activity through CRISPR-based perturbation.

GWAS studies have proven very informative in identifying highly associated regions of interest within the genome, but very often the identified SNP is not causal and the effector gene still has to be elucidated. In addition, target validation for

could play a direct transcriptional regulatory role. <sup>(22)</sup> EPDR1 is also known to interact with various extracellular matrix proteins which are known to play a role in osteoblast differentiation. Furthermore, EPDR1 peptides have been shown to play a role in transcriptional regulation. AP-1 is a transcription factor involved in osteoblast differentiation through TGF- $\beta$  and vitamin D <sup>(25,26)</sup>; thus AP-1 transcriptional activity may reveal another mechanism of regulation in this setting, and therefore warrants follow-up efforts. These other studies suggest that EPDR1 represents an attractive novel target for bone metabolism. While EPDR1 knockdown impairs gene expression, elucidating the impact of reduced EPDR1 on osteoblast gene expression protein level will be essential.

While the present study confirms a regulatory role for the proxy SNPs in *EPDR1* gene regulation, due to the tight proximity of the three BMD-associated SNPs, the identity of the exact causal variant remains unknown. Identifying the exact SNP(s) involved will require more precise techniques than CRISPR-Cas9 in this region. Other sequence specific techniques like CRISPR inhibition (CRISPRi) and CRISPR activation (CRISPRa) which have no endonuclease activity but only block or activate transcription at the sgRNA guide position without modifying the genome or CRISPR-Cas9 mediated synchronous programmable adenine and cytosine editor (SPACE) <sup>(24)</sup> may be used for targeting of the individual alleles. Potential binding sites for transcription

This work also builds on efforts by other groups to connect osteoporosis signaling signals directly to the transcription of a distal gene, and thus downstream effects. While additional studies are needed to further explore the regulation of the 'STARD3NL' locus and to understand its mechanistic function, our current findings point to *EPDR1* being involved in bone differentiation processes and thus a potential target for BMD-related osteoporosis studies.



## **ACKNOWLEDGMENTS**

This research was funded by the Children's Hospital of Philadelphia a  
HG010067, R01 AR066028 and R01 HD100406. Dr. Grant is funded  
Endowed Chair for Diabetes Research.

## **DISCLOSURES**

The authors report no conflicts of interest

## REFERENCES

1. Morris JA, Kemp JP, Youlten SE, Laurent L, Logan JG, Cha Forgetta V, Kleinman A, Mohanty ST, Sergio CM, Quinn J, Luco A-L, Vijay J, Simon M-M, Pramatarova A, Medina-Gomez GH, Ghirardello EJ, Butterfield NC, Curry KF, Leitch VD, Sparke Mannan NS, Komla-Ebri DSK, Pollard AS, Dewhurst HF, Ha 23andMe Research Team, Adams DJ, Vaillancourt SM, Kap Cooper C, Reeve J, Ntzani EE, Evangelou E, Ohlsson C, K Kiel DP, Tobias JH, Gregson CL, Harvey NC, Grundberg E, Lelliott CJ, Hinds DA, Ackert-Bicknell CL, Hsu Y-H, Mauran Williams GR, Bassett JHD, Evans DM, Richards JB. An atlas of genetic loci associated with osteoporosis in humans and mice. *Nature Genetics*. *Nature* Feb;51(2):258–66.
2. Richards JB, Zheng H-F, Spector TD. Genetics of osteoporosis: association studies: advances and challenges. *Nat. Rev. Genet.* 2012;13(8):576–88.
3. Kemp JP, Morris JA, Medina-Gomez C, Forgetta V, Warrington Zheng J, Gregson CL, Grundberg E, Trajanoska K, Logan JG, PC, Ghirardello EJ, Allen R, Leitch VD, Butterfield NC, Komla Curry KF, White JK, Kussy F, Greenlaw KM, Xu C, Harvey NC, Greenwood CMT, Maurano MT, Kaptoge S, Rivadeneira F, Ackert-Bicknell CL, Bassett JHD, Williams GR, Richards JB. Discovery of 153 new loci associated with heel bone mineral density and of GPC6 in osteoporosis. *Nature Genetics*. 2017 Oct;49(10):1100–11.
4. Chesi A, Mitchell JA, Kalkwarf HJ, Bradfield JP, Lappe JM, McCormack SE, Gilsanz V, Oberfield SE, Hakonarson H, S Zemel BS, Grant SF. A Genomewide Association Study Identifies Loci, at SPTB and IZUMO3, Influencing Pediatric Bone Mineral Density at Skeletal Sites. *Journal of Bone and Mineral Research*. 2017;32(12):2233–43.
5. Chesi A, Mitchell JA, molecular HKH, 2015. A trans-ethnic genome-wide association study identifies gender-specific loci influencing pediatric areal bone mineral density. *PLoS One*. 2015;10(12):e0144000.

interactions implicate effector genes at GWAS loci for bone  
Communications. Springer US; 2019 Mar 13;:1–11.

10. Xia Q, Chesi A, Manduchi E, Johnston BT, Lu S, Leonard M, EF, Huang P, Wells AD, Blobel GA, Johnson ME, Grant SF. A presumed causal variant within TCF7L2 resides in an element that regulates the expression of ACSL5. *Diabetologia*. Springer Berlin Heidelberg; 2016 Nov;59(11):2360–8.
11. Harris SA, Enger RJ, Riggs LB, Spelsberg TC. Development of a conditionally immortalized human fetal osteoblastic cell line. *Mineral Research*. John Wiley & Sons, Ltd; 1995 Feb 1;10(2):105–11.
12. Engler C, Kandzia R, Marillonnet S. A One Pot, One Step, PCR-Free Gateway with High Throughput Capability. *EI-Shemy HA, editor. PLoS Science*; 2008 Nov 5;3(11):e3647–7.
13. Engler C, Gruetzner R, Kandzia R, Marillonnet S. Golden Gate DNA Shuffling Method Based on Type IIa Restriction Enzymes. *PLoS ONE*. Public Library of Science; 2009 May 14;4(5):e5523.
14. Engler C, Marillonnet S. Generation of Families of Construct Libraries by Gateway Gate Shuffling. In: Lu C, Browse J, Wallis JG, editors. *cDNA Libraries: Applications*. Totowa, NJ: Humana Press; 2011. pp. 167–81.
15. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the  $2^{-\Delta\Delta Ct}$  method. *Nat Protoc*. Nature Publishing Group; 2008 Jun 1;3(6):1556–62.
16. Orimo H. The mechanism of mineralization and the role of osteoblasts in health and disease. *J Nippon Med Sch. The Medical Association of Japan School*; 2010 Feb;77(1):4–12.
17. Serguienko A, Wang MY, Myklebost O. Real-Time Vital Miniplex Quantification during In Vitro Osteoblast Differentiation. *BioRx*; 2018 May 30;:1–5.
18. Wanachewin O, Boonmalacrat K, Bothacharoen P, Boontra

21. Nimmrich I, Erdmann S, Melchers U, Chtarbova S, Finke U, Oertel M, Hoffmann W, Müller O. The novel ependymin related protein EPDR1 is expressed in colorectal tumor cells. *Cancer Lett.* 2001 Apr 1;170(1-2):115-22.
22. Deshmukh AS, Peijs L, Beaudry JL, Jespersen NZ, Nielsen M, Larsen TJ, Bayarri-Olmos R, Prabhakar BS, Helgstrand C, Kjaer A, Tang-Christensen M, Sanfridson A, Garred P, Privé G, Gerhart-Hines Z, Nielsen S, Drucker DJ, Mann M, Scheele M. Comparative Mapping of the Secretomes of Human Brown Adipocytes Reveals EPDR1 as a Novel Batokine. *Cell Metabolism.* Elsevier; 2018 Jun 5;30(5):963–7.
23. Shashoua VE, Adams D, Boyer-Boiteau A. CMX-8933, a peptide inhibitor of the glycoprotein ependymin, promotes activation of AP-1 transcription factor in neuroblastoma and rat cortical cell cultures. *Neurosci. Lett.* 2007;421(1-3):7-10.
24. Grünewald J, Zhou R, Lareau CA, Garcia SP, Iyer S, Miller M, Aryee MJ, Joung JK. A dual-deaminase CRISPR base editor enables adenine and cytosine editing. *Nat. Biotechnol.* Nature Publishing Group; 2019 Jul 1;38(7):861–4.
25. Trzeciakiewicz A, Habauzit V, Horcajada M-N. When nutrition meets health: function: molecular mechanisms of polyphenols. *Nutr. Res.* Pennsylvania Libraries; 2009 Feb 26;22(1):68–81.
26. Chang J, Wang Z, Tang E, Fan Z, McCauley L, Franceschi T, PH, Wang C-Y. Inhibition of osteoblastic bone formation by ependymin. *Med.* Nature Publishing Group; 2009 May 17;15(6):682–9.
27. Lin X, Yang H, Wang L, Li W, Diao S, Du J, Wang S, Dong X. Ependymin enhanced the osteogenic differentiation of mesenchymal stem cells through formation of YAP/RUNX2 complex and BARX1 transcription factor. *Stem Cell Res.* 2015;52(1):e12522–11.
28. Chen XF, Zhu DL, Yang M, Hu WX, of YDTAJ, 2018. An osteogenic transcription factor 1p26-12 acts as an allele-specific enhancer to modulate L

## FIGURE LEGENDS

**Figure 1. Promoter Capture C interactions between the *EPDR1* gene and proxy SNPs.** rs1524068 ( $r^2=1.0$ , dark green), rs6975644 ( $r^2= 0.553249$ , orange), and rs10995712, light green) located at the '*STARD3NL*' locus (sentinel SNP) are shown. The color arcs represent C contacts between the proxy SNPs and the *EPDR1* gene promoter are shown (color arcs) and located in open chromatin regions (OCRs). The 204bp region is indicated below the proxy SNPs with an arrowhead. All genes in the region are indicated at scale.

**Figure 2. Multiplexed sequencing of CRISPR-edited hFOB1.19 cells confirms proxy SNP deletions and reveals the efficient sgRNA pair.** Three replicates are shown. Teal indicates wild-type sequence, pink indicates deletions, and the red bars indicate proxy SNP locations. The US3/DS3 combination produced the highest percentage of deletions (average 59.3%) followed by the US1/DS3 combination (average 39.6%). Variability in the CRISPR cut sites is indicated by error bars.

**Figure 4. Western Immunoblotting reveals a decrease in EPDR1 p**  
**CRISPR-edited hFOB1.19 cells differentiated for 7 days.** Three biological replicates are shown for each condition. **A.** Western immunoblotting detected bands for EPDR1 (25kDa) with a decrease in EPDR1 band intensities in differentiated hFOB1.19 samples. Equal loading was verified with the housekeeping protein GAPDH (55kDa). **B.** Quantification of the upper band (U) and middle band (M) in differentiated samples shows a decrease of ~90% on average for both U and M bands compared to empty controls (empty vector).

**Figure 5. Alkaline phosphatase staining (ALP) is reduced in CRISPR-edited hFOB1.19 cells differentiated for 5 days.** Three biological replicates are shown for each condition. **A.** ALP staining of plates grown under both permissive (33.5°C) and differentiated (39.5°C) conditions. Purple color indicates alkaline phosphatase activity. **B.** Quantification of ALP staining shows an average 61% decrease in ALP staining in differentiated hFOB1.19 cells compared to empty controls. **pValues (t-test):** \* = Empty Vector-39.5°C vs CRISPR pool-39.5°C, all p-values are  $p < 0.0005$ .

## SUPPLEMENTARY FIGURE AND TABLE LEGENDS

**Figure S1. Bright field and Texas red fluorescent microscopy of hFOB1.19 cells at 10X magnification.** Comparison of the same field under both bright field and Texas red fluorescence. Red fluorescence shows a high number of mCherry positive cells in both control and CRISPR pool cells for all three biological replicates. Scale bar = 200µm.

**Figure S2. CRISPR-cas9 primer design for the '*STARD3NL*' locus.** Proxy SNPs (rs940347, rs6975644, and rs1524068) are indicated at the top. The CRISPR-cas9 target region, sgRNAs are indicated by boxes, PCR primers are indicated by horizontal lines, and sequencing primers are indicated by tailed-arrows. Diagram is to scale. Locations are indicated by vertical lines.

**Figure S3. RNAi targeting of *EPDR1* expression decreases alkaline phosphatase activity (ALP) in differentiated hFOB1.19 cells.** **A.** Alkaline phosphatase staining is visible during permissive growth (33.5°C). *EPDR1* RNAi decreases ALP staining upon activation of alkaline phosphatase during differentiation (39.5°C). **B.** Quantification shows a doubling of ALP activity during 5 days of differentiation (39.5°C).

the two was used to calculate transduction efficiency and averaged  $\pm$  biological replicates.

**Figure S5. PCR products generated across the 'STARD3NL' (sense) proxy SNPs region (rs1524068, rs6975644, rs940347) from genomic DNA of deletions in CRISPR-edited hFOB1.19 cells.** The wild type PCR product is 2370bp, the smallest deletion (595bp) generates a PCR product band of 1775bp, the largest deletion (1739bp) generates a PCR product band size of 631bp. All other combinations generate PCR products within the CRISPR deletion range. Data shown are biological replicates.


**Figure S6. RT-qPCR of CRISPR-edited hFOB1.19 derived RNA revealed a dramatic decrease in EPDR1 mRNA expression levels in CRISPR-edited cells differentiated (39.5°C) for 7 days.** All three biological replicates were compared to Empty Vector. pValues (t-test): # = Empty Vector vs CRISPR positive control, \* = Empty Vector-39.5°C vs CRISPR-39.5°C, all marked samples have





Author Manuscript



*EPDR1* at 'STARD3NL' Locus (

chr7 (p14.1) 7p21.3 21.115.3 p14.3 p14.1 11.2 11.21 11.22 11.23 7q21













Figure 1

Author Manuscript

# *EPDR1* at '*STARD3NL*' Locus (Sentinel rs6959212)




Figure 2

Author Manuscript






Figure 3






Figure 4



# Figure 5

A



B

